JCR Pharmaceuticals (OTCMKTS:JCRRF – Get Free Report) is projected to release its results after the market closes on Thursday, October 29th. Analysts expect JCR Pharmaceuticals to announce earnings of $0.0011 per share and revenue of $80.16 million for the quarter.
JCR Pharmaceuticals Price Performance
JCR Pharmaceuticals stock opened at $3.73 on Wednesday. The firm has a fifty day simple moving average of $3.47 and a two-hundred day simple moving average of $3.79. JCR Pharmaceuticals has a twelve month low of $3.15 and a twelve month high of $3.73.
About JCR Pharmaceuticals
JCR Pharmaceuticals Co, Ltd. is a Japan-based biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company’s research programs include biologics, enzyme replacement therapies, growth hormone products, and regenerative medicine, with an emphasis on applying biotechnology to improve patient care.
JCR’s portfolio includes therapies for rare lysosomal storage disorders and pediatric diseases.
Read More
- Five stocks we like better than JCR Pharmaceuticals
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for JCR Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JCR Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
